Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday November 10, 2009

DrStockPick.com Stock Report!

**************************************************************

PowerSafe Technology Corporation (PSFT.PK) subsidiary Amplification Technologies Inc. (www.amplificationtechnologies.com) (ATI), is offering higher performance thermoelectrically cooled discrete amplification single photon counting solid state photodetectors. These photodetectors are mounted on a two stage thermoelectric cooler inside a hermetically sealed TO8 package and can be operated down to a temperature of -30oC.

Glimcher Realty Trust (NYSE: GRT), one of the country’s premier retail REITs today announced the appointment of Ward A. Kampf, as Vice President, Leasing, effective Wednesday, November

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday November 6, 2009

DrStockPick.com Stock Report!

**************************************************************

PowerSafe Technology Corporation (PSFT.PK) subsidiary Amplification Technologies Inc. (www.amplificationtechnologies.com) (ATI), is offering higher performance thermoelectrically cooled discrete amplification single photon counting solid state photodetectors. These photodetectors are mounted on a two stage thermoelectric cooler inside a hermetically sealed TO8 package and can be operated down to a temperature of -30oC.

Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today reported financial results and operational updates

...

Neptune Technologies & Bioressources Inc. announced that the patent, “KRILL EXTRACTS FOR PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR DISEASES,” was successfully issued in Europe, marking an integral achievement in eliminating competition of other entities focused on krill extract in the European cardiovascular market.

The issuance of the patent is expected to thwart unregulated marketing of krill oil and relative products.

“Recently, we observed players cheating on the market and misleading consumers by selling krill oil in Europe without any regulatory approval. We also noticed that they advertise unproven health benefits with their products as well as infringe on our patents. This was surprising until we realized who were involved. These situations will be addressed as required,” Henri Harland, CEO and president of Neptune stated in the press release.

The company also announced that the European Food Safety Authority (EFSA) signed the approval of Neptune Krill Oil as a Novel Food and

...

Obesity is a leading risk factor behind many cardiovascular diseases, cancers and type 2 diabetes. According to the Centers for Disease Control and Prevention, in the past 20 years there has been a dramatic increase in obesity. Though public awareness has prompted more Americans to hit the gym and lead healthier lifestyles, calories and fat in beverages such as juices, energy and soft drinks are often overlooked, subtly contributing to weight-gain and health issues.

Celsius Holdings Inc. has developed an original drink to generate the opposite effect. The company’s Celsius® calorie burning beverage has been scientifically proven to burn approximately 100 calories per can through boosting metabolism and providing sustained energy over a three-hour period.

The company today announced increased availability of Celsius, as the product is available at approximately 1,800 SUPRERVALU stores.

“We are thrilled to be carried by SUPERVALU, a leading grocery retailer with unsurpassed recognition in the

...

Adeona Pharmaceuticals, Inc.

(Public, AMEX:AEN)

StocksHaven Investments takes a look at Adeona Pharmaceuticals, Inc. which currently has three blockbuster drugs in phase III, and are coming close to NDA status. The first being Trimesta, which tackles Multiple Sclerosis (MS) and Post-partum Depression. Secondly, Zinthionein, a product seeking treatment for Age Related Macular Degeneration (AMD). Lastly, Oral dnaJP1 which is an immunotherapy for rheumatoid arthritis (RA) patients. If these products aren’t enough to entice your way into purchasing this stock, take a look at the recent $5 million dollar cash infusion from the National Multiple Sclerosis Society (NMSS), billions of dollars in product market potential, purchasing of Hartlab LLC, an independent Chicago-area CLIA-certified clinical reference laboratory, an experienced management team that will have you feeling like a kid in a candy store, and to

...

ARCA Biopharma, Inc.

(Public, NASDAQ:ABIO)

Heart failure has always been one of the predominant fatal human conditions, therefore this week I will be focusing on a company which has developed a highly successful treatment.

The broad world market for this drug is truly spectacular.

Key Facts: Heart failure becomes more common with increasing age. About 1 in 35 people aged 65-74 years have heart failure. This increases to about 1 in 15 of people aged 75-84 years, and to just over 1 in 7 people aged 85 years and above. It is uncommon in younger people.

It is difficult to give an outlook (prognosis) for an individual. In general, the more severe the heart failure, the worse the outlook. In many cases, the symptoms remain at a stable level for quite some time (months or years) before becomming worse. In some cases the severity

...

With stocks having been beaten down so badly these past few quarters, investors are getting tired of losing money. However, for those of us who are not about to retire, we have to allow some room for patience in our investing strategies. Investing in a company whose stock price appreciates year-over-year is optimal, but if you’ve got some time to spare, invest in companies that you know will be more valuable 10 to 15 years down the road. With heart disease persisting as the number one killer worldwide, you should be looking to prop up your portfolio over the long run with stocks dedicated to fighting heart disease . Combined with the aging world population, these two stocks are poised to capitalize on the declining health of the eldest generation:

Medtronic Inc.

Medtronic Inc. [MDT:

...

CV Therapeutics, Inc. (CVTX) is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT currently has several potential growth drivers.

The company received some very positive news on November 5, 2008 when the FDA approved the company's key drug, Ranexa, for use in the first-line indication for chronic angina. The new expanded label removed previous cautionary language limiting use with other cardiovascular medications, and now allows management to promote the drug with added claims on arrhythmias, atrial fibrillation, and a reduction in hemoglobin A1c. Ranexa prescriptions grew nicely in the third quarter 2008, and all systems are go for significantly improved sales in 2009 thanks to the newly expanded label.

We are encouraged by the strong fundamentals at CVT and believe the shares are looking attractive at prices below $8.

Read the

...

Durect Corp. (DRRX) utilizes 6 proprietary drug delivery technologies to develop pharmaceutical systems that enhance treatment capabilities in the areas of chronic pain, cardiovascular diseases, and central nervous system disorders.The company recently received disappointing news when its lead pipeline candidate, Remoxy, failed to receive FDA approval in December 2008. While this news is a setback for the company, we believe that the product will ultimately receive approval and should see significant demand due to its ability to reduce the potential of drug abuse / misuse. Meanwhile, we remain optimistic on the remaining candidates in Durect's pipeline which consists of three candidates in phase II development.Moreover, we were pleased to hear about Durect's partnership deal with Alpharma (ALO) for Eladur. In our opinion, the current share price represents an attractive entry point. We thus rate the shares a Buy with a revised price target ...

BioHeart is a biotechnology corporation that develops devices designed to aid in the diagnosis, monitoring, and treatment of cardiovascular diseases. The company aims to improve heart disease sufferers’ quality of life, while attempting to reduce the normally exorbitant costs associated with cardiologic treatments.

In a press statement issued on Thursday, the company announced that it had received a United States Patent and Trademark Office Notice of Allowance for nine new patent claims, which pertain to using electrical signals to stimulate heart cell regeneration. BioHeart’s new technologies are a significant step forward in the field of cardiovascular treatment in that they utilize fundamental electro-chemical genetic instructions to “teach” undifferentiated stem cells to grow into heart muscle. This process will aid heart failure victims in regrowing damaged heart tissue, and could potentially save lives.

“The best way to predict the future is to create it,” said BioHeart’s director of surgical and clinical

...